Richie Khanna

Richie Khanna, Ph.D. joined LEXEO Therapeutics as Vice President, Non-clinical Development and Bioanalytical Development in Q1 2021. Prior to LEXEO, Dr. Khanna worked at Amicus Therapeutics for 16 years starting as employee #7, leading the comprehensive Non-clinical Development programs. Dr. Khanna established an In Vivo Pharmacology Department of 15 scientists at Bachelors, Masters, and Ph.D. levels and led all IND-enabling animal studies for small molecules, Biologics, and AAV gene therapy programs. Dr. Khanna's significant non-clinical achievement was global apprOval of Galafold for Fabry disease and successful rolling non-clinical BLA submission for ATB200 for Pompe disease. Dr. Khanna received her Ph.D. in Molecular Biology from the University of Delhi, India, and obtained her first post-doctoral research experience in Biomedical Science from Tufts University and second in Neuroscience from Rutgers University.